Other Assets - Additional Information (Detail)
|
3 Months Ended | 9 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 9 Months Ended | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2013
USD ($)
|
Jun. 30, 2013
USD ($)
|
Jun. 30, 2012
USD ($)
|
Dec. 31, 2012
OctoPlus N.V. [Member]
EUR (€)
|
Jun. 30, 2013
ViaCyte, Inc. [Member]
USD ($)
|
Sep. 30, 2012
OctoPlus N.V. [Member]
USD ($)
|
Dec. 31, 2010
Nexeon MedSystems, Inc. [Member]
USD ($)
|
Jun. 30, 2013
Nexeon MedSystems, Inc. [Member]
USD ($)
|
Jun. 30, 2013
ThermopeutiX, Inc. [Member]
USD ($)
|
Dec. 31, 2012
Investment In Vessix Vascular, Inc. [Member]
USD ($)
|
Sep. 30, 2010
Investment In Vessix Vascular, Inc. [Member]
USD ($)
|
Jun. 30, 2013
Maximum [Member]
USD ($)
|
Jun. 30, 2012
Maximum [Member]
USD ($)
|
Jun. 30, 2013
Maximum [Member]
USD ($)
|
Jun. 30, 2012
Maximum [Member]
USD ($)
|
Jun. 30, 2013
Maximum [Member]
ViaCyte, Inc. [Member]
|
Jun. 30, 2013
Maximum [Member]
Nexeon MedSystems, Inc. [Member]
|
Jun. 30, 2013
Maximum [Member]
ThermopeutiX, Inc. [Member]
|
Dec. 31, 2012
Maximum [Member]
Investment In Vessix Vascular, Inc. [Member]
USD ($)
|
Jun. 30, 2013
Maximum [Member]
CeloNova BioSciences, Inc. [Member]
|
|
Other Assets [Line Items] | ||||||||||||||||||||
Investment cost, cost method | $ 5,200,000 | $ 900,000 | $ 6,500,000 | $ 1,200,000 | ||||||||||||||||
Offer price to purchase all issued and outstanding ordinary shares | € 0.52 | |||||||||||||||||||
Gain on sale of investments | 100,000 | |||||||||||||||||||
Impairment loss on other assets | 4,700,000 | 4,100,000 | ||||||||||||||||||
Company's ownership percentage | 5.00% | 20.00% | 20.00% | 5.00% | ||||||||||||||||
Additional impairment loss other than temporary | 100,000 | |||||||||||||||||||
Cost method of investment | 400,000 | 2,500,000 | ||||||||||||||||||
Impairment loss on investment | 2,400,000 | |||||||||||||||||||
Gain on sale of investment | 1,460,000 | 172,000 | 1,200,000 | |||||||||||||||||
Potential proceeds on achievement of future milestones | 4,200,000 | |||||||||||||||||||
Revenue recognized from activity with companies in which it had strategic investment | $ 100,000 | $ 100,000 | $ 100,000 | $ 100,000 |